Research ArticleInfectious Disease

TORC1 inhibition enhances immune function and reduces infections in the elderly

See allHide authors and affiliations

Science Translational Medicine  11 Jul 2018:
Vol. 10, Issue 449, eaaq1564
DOI: 10.1126/scitranslmed.aaq1564

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Dialing down TORC1 dials up immunity

Aging may be regulated by a discrete set of intracellular proteins including the mechanistic target of rapamycin (mTOR) kinase. mTOR functions within two multiprotein complexes called TORC1 and TORC2. Inhibition of TORC1 has extended life span in every species studied to date and ameliorated multiple aging-related pathologies including declining immune function. Mannick et al. now show that low-dose TORC1 inhibitor therapy in elderly humans decreased the incidence of all infections, improved influenza vaccination responses, and up-regulated antiviral immunity. Thus, targeting the TORC1 pathway that regulates aging may have clinical benefits for elderly humans including improvement in immune function and decreased infection rates.